Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...

A human ear attached to a woman’s foot sounds like a stunt from a horror film, yet it is the centerpiece of a real, carefully planned medical rescue. In a world first, surgeons in China temporarily ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic) Both studies achieved the secondary endpoint of im ...

Explaining the findings, a Research Scientist of the CSIR-Water Research Institute, Zita Naangmenyele Abuntori, said the ...

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of improv ...

A vanishingly rare genetic glitch in a single enzyme can erase a newborn’s brain cells in a matter of weeks, leaving doctors ...

The total value of an artist’s artworks sold at auction over a specific period. This metric reflects the artist’s overall market activity and demand in monetary terms. The middle value of all realized ...

Three probes each detecting a locus on the proximal long arm of the Y chromosome were partially sequenced. Thus, 3 sets of novel primers were developed which enable PCR detection of these 3 loci. Five ...

Drawing from a broad spectrum of social, biological, health, and physical science disciplines, Nature Human Behaviour publishes research of outstanding significance into any aspect of individual or ...